Clinical Trial

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

Study acronym: TRUST-II
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2021-06-08; most recent amendment 2026-01-05.
Status change: Recruiting → Active, Not Recruiting 2025-10-14
Status change: Not Yet Recruiting → Recruiting 2021-12-07
Trial Details
NCT Number NCT04919811
Lead Sponsor Nuvation Bio Inc.
Conditions Non Small Cell Lung Cancer
Enrollment 217 participants
Start Date 2021-09-01
Primary Completion 2025-06-11 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-07